中药辨证论治联合介入及索拉非尼对H22肝癌荷瘤小鼠疗效的实验研究  

Efficacy of TCM differential treatment combined interposition and sorafenib on H22 hepatocarcinoma mice

作　　者：张园园[1] 方肇勤[1] 王艳明[1] 潘志强[1] 卢文丽[1] 刘小美[1] 

机构地区：[1]上海中医药大学基础医学院,上海201203

出　　处：《中西医结合肝病杂志》2012年第1期34-37,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：上海市教委学科建设项目;国家科技重大专项课题(No.2009ZX09502-018)

摘　　要：目的:比较与评价H22肝癌小鼠单纯西医及中西医联合治疗方案的疗效。方法:采用H22腋下实体瘤昆明种雄性小鼠,应用小鼠标准化、计量化辨证方法,观察复合化疗制剂肿瘤局部注射联合索拉非尼口服、单纯西医治疗方案,及其西医治疗方案联合中药辨证论治方案对小鼠带瘤生存时间、抑瘤率和证候的疗效。结果:3种治疗方案均有一定的抑瘤作用,而中西医结合辨证论治方案较单纯西医方案在小鼠带瘤生存时间、对气血阴阳证候的影响,以及胸腺和脾脏重量等方面,具有一定的优势。结论:中西医结合辨证论治原发性肝癌的治疗方案较单纯西医治疗方案具有一定的优势。Objective：To assess the efficacy of simple western medicine（WM） and wm combined traditional Chinese medicine（TCM） for treating H22 hepatocarcinoma mice.Methods：Observed male Kunming mice with tumor survival,inhibition rate and symptoms in order to estimate therapeutic effects of tumor local compound chemotherapy and sorafenib oral administration,as well as which of pure wm combined TCM differential treatment,by standardized and quantitative of syndrome differentiation methods.Results：All three therapies had a certain inhibitory effect,which wm combined TCM possessed certain superiority in survival time,the impact to the syndrome of Qi,blood,Yin,Yang,and thymus and spleen weight.Conclusion：wm Combined TCM have certain advantage than simple wm for treating H22 hepatocarcinoma mice.

关 键 词：肝癌 小鼠 辨证论治 介入/治疗 索拉非尼/药理作用 疗效评价 

分 类 号：R735.7[医药卫生—肿瘤]